doi: 10.7501/j.issn.0253-2670.2025.06.004
Objective To study the chemical constituents of of Angelica gigas, and evaluate the activity of the isolated monomer compounds against prostate cancer. Methods The ethyl acetate extract of A. gigas was systematically isolated and purified using silica gel column chromatography and semi-preparative HPLC. The structures of the isolated monomer compounds were characterized by a combination of spectroscopic methods, including nuclear magnetic resonance, high resolution mass spectrometry. The anti-prostate cancer activity of the compounds was evaluated using the CCK-8 assay, and network pharmacology was employed to predict the targets, functions, and pathways of the active ingredients of A. gigas against prostate cancer, which was further verified by Western blotting (WB) experiments. Results A total of 33 compounds were isolated from the ethyl acetate fraction of A. gigas and identified as umbelliferone (1), skimmin (2), scopoletin (3), 7-demethylsuberosine (4), 6,7-dimethoxycoumarin (5) devenyol (6), bergapten (7), isoimperatorin (8), cnidicin (9), imperatorin (10), xanthotoxol (11), xanthotoxin (12), nodakenetin (13), marmesin (14), nodakenin (15), isopsoralen (16), oroselol (17), (±)-vaginidiol (18), columbianadin (19), xanthyletin (20), decursinol (21), decursin (22), decursinol angelate (23), (+)-lomatin (24) (+)-cis-khellactone (25), catechin (26), quercetin (27), myricetin (28), nicotinic acid (29), ferulic acid (30), chlorogenic acid (31), 5-(hydroxymethyl)furfural (32), 5,5¢-dibutoxy-2,2¢-bifuran (33). Compounds 1, 4, 6, 8, 12, 13, 19, and 21—24 exhibited inhibition of prostate cancer cell proliferation. The five compounds with the most significant cancer inhibition effects (1, 4, 21—23) were further evaluated for their anti-prostate cancer activities at multiple concentrations. Among them, compounds 22 and 23 showed the strongest inhibition of prostate tumors. A total of 11 core anti-prostate cancer targets of the chemical components in A. gigas were identified through network pharmacology prediction, including threonine kinase (AKT), epidermal growth factor receptor (EGFR), cyclin D1 (CCND1), prostaglandin-endoperoxide synthase 2 (PTGS2), and others. KEGG pathway enrichment screening revealed signaling pathways involved in the cancer pathway, the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) pathway, and the EGFR signaling pathway. Western blotting analysis confirmed that the active ingredients in A. gigas exerted anti-prostate cancer effects by inhibiting the expression of AKT, a key protein in the PI3K/AKT pathway. Conclusion Compounds 6, 16, 17, 24, and 33 were identified for the first time from this genus, while compounds 18, 25, and 32 were found for the first time from this species. Compounds 1, 4, 21—23 showed better inhibition of prostate cancer cell proliferation, with compounds 22 and 23 having the strongest inhibitory effect, which demonstrated their anti-prostate cancer effects by inhibiting the expression of AKT, a key protein in the PI3K/AKT pathway.